Literature DB >> 9506363

Bone marrow staging in patients with non-Hodgkin's lymphoma: is flow cytometry a useful test?

M J Naughton1, J L Hess, M M Zutter, N L Bartlett.   

Abstract

BACKGROUND: Flow cytometric analysis of bone marrow often is used as an adjunct to morphologic evaluation in the staging of patients with non-Hodgkin's lymphoma (NHL). The goal of this study was to define objectively the benefit of flow cytometry in this setting.
METHODS: The authors reviewed retrospectively all bone marrow specimens submitted between January 1992 and December 1994 to the Washington University Department of Pathology for flow cytometric immunophenotyping to rule out NHL. Results of morphologic examination and flow cytometry were reviewed independently and the ability to detect bone marrow involvement compared.
RESULTS: Two hundred and seventy-three bone marrow specimens from 190 patients with an established diagnosis of NHL were submitted for flow cytometric analysis at initial presentation, restaging, and/or recurrence. Morphologic evaluation was negative in 69%, positive in 23%, and equivocal in 8%. Flow cytometry was negative in all but 1 morphologically negative bone marrow specimens and 40% of morphologically involved bone marrow specimens. Two of 23 morphologically equivocal bone marrow specimens were positive by flow cytometry. An additional 86 specimens were obtained to rule out NHL in patients without an established diagnosis of NHL. The majority of patients had a history of human immunodeficiency virus infection, cytopenia, or unexplained fevers. Morphologically, one specimen was involved with NHL, 5 were equivocal, and 80 were negative. All specimens were negative by flow cytometry.
CONCLUSIONS: In this study, flow cytometric analysis improved the detection of NHL in bone marrow in only 3 of 273 samples, 2 of which were suspicious morphologically. Flow cytometry of bone marrow aspirates has a limited role in the routine staging and follow-up of patients with an established diagnosis of NHL.

Entities:  

Mesh:

Year:  1998        PMID: 9506363     DOI: 10.1002/(sici)1097-0142(19980315)82:6<1154::aid-cncr21>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma.

Authors:  M Ozgüroglu; G Esen Ersavasti; G Demir; H Aki; F Demirelli; K Kanberoglu; N Mandel; E Büyükünal; S Serdengeçti; B Berkarda
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

2.  A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders.

Authors:  S P Sah; E Matutes; A C Wotherspoon; R Morilla; D Catovsky
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

3.  Bone marrow flow cytometry in staging of patients with B-cell non-Hodgkin lymphoma.

Authors:  Borahm Kim; Seung-Tae Lee; Hee-Jin Kim; Sun Hee Kim
Journal:  Ann Lab Med       Date:  2015-02-12       Impact factor: 3.464

4.  Bone Marrow Involvement by Aggressive B Cell Lymphoma Undetected by Aspirate Immunophenotyping.

Authors:  Habib Moshref Razavi
Journal:  J Hematol       Date:  2021-02-06

5.  Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).

Authors:  Dipti Talaulikar; Bruce Shadbolt; Jane E Dahlstrom; Anne McDonald
Journal:  J Hematol Oncol       Date:  2009-11-22       Impact factor: 17.388

6.  Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry.

Authors:  Afaf Abdel-Aziz Abdel-Ghafar; Manal Ahmed Shams El Din El Telbany; Hanan Mohamed Mahmoud; Yasmin Nabil El-Sakhawy
Journal:  Hematol Rep       Date:  2012-02-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.